Kodiak Sciences KOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with ...

Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti ...

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical ... Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for ...

March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq ... The primary endpoint is the proportion of eyes improving ≥2 steps on Diabetic Retinopathy Severity Scale ("DRSS") from baseline at Week ...

So should Kodiak Sciences (NASDAQ:KOD) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to ...

So should Kodiak Sciences (NASDAQ:KOD) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...